{'fraction_non_alphanumeric': 0.030619865571321882, 'fraction_numerical': 0.014189693801344288, 'mean_word_length': 5.350710900473934, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Generic: The Unbranding of Modern Medicine by Jeremy A. Greene (review)

In this thoroughly engaging social, cultural, and political history of generic drugs, Jeremy Greene details the transformation of the generic drug from an object of suspect manufacturing practices and limited regulation in the 1950s to the putative “solution to problems of cost and access in [global] health care” by the early twenty-first century (p. 243). At the center of this transformation were the scientific, clinical, political, and economic debates over generic substitution. In providing this rich account, Greene builds upon the work of scholars who have examined the history and anthropology of generic drugs.1 Particularly compelling is Greene’s analysis in chapter 9 of the development of New York’s statewide formulary that came to supplant the efforts of the Food and Drug Administration to develop its own list of interchangeable generic drugs in the late 1970s. In the 1980s, Greene argues, while the American Medical Association and the research-based pharmaceutical industry came to accept the legality of generic substitution, the political debate shifted to the interchangeability of “me-too” drugs. Chapter 12 is instructive because using the examples of “me-too” cephalosporins, which were interchangeable, and beta-blockers, which were not,